VERTIGIS
VertiGIS, a leading geographic information systems (GIS) solution provider and software developer, announced today the completed acquisition of longstanding development partner KMS Computer GmbH. KMS is an established and trusted computer-aided facility management (CAFM) software specialist based in Dresden, Germany.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210414005039/en/
VertiGIS is backed by global, technology-based investment firm Battery Ventures, who began acquiring GIS and location technology-focused companies under the brand in 2017.
Best known for the GEBman software suite, KMS has helped municipal, industry, service, and utility companies with their facility- and document management needs since 1990. Their flexible, end-to-end solutions – based upon the latest web technologies and suitable for in-house or mobile use – integrate access and analysis of factual data, documents, and spatial information for plants, real estate, and capital goods.
For the past 15 years, KMS has worked with VertiGIS to bring ProOffice – a process-oriented software solution with optional GIS connectivity for infrastructure workflows, and built upon GEBman technology – to German, Austrian, and Swiss customers. The integration of KMS into VertiGIS ensures that the strategic planning and development of ProOffice and GEBman continue to be closely coordinated.
"After 30 years, it was time for me to hand over the company to the next generation,” explains Konrad Schulze, founder and Managing Director of KMS. “Due to the successful partnership and cooperation that has existed between KMS and VertiGIS for many years, I know we can combine the greatest strengths of both organizations and expect our joint customers to benefit from the expanded expertise and industry-leading know-how we have developed over the years.”
“Previous sales partners have now become colleagues, and we are looking forward to working together as one team.”
Schulze’s son, Sebastian, will transition from CTO at KMS to assume the co-role of Managing Director together with VertiGIS veteran Theodor Meusburger. KMS’s solution will become an integral part of the VertiGIS offering for all customers and business segments and will be further supported in sales and software development by VertiGIS’s global business units and teams.
“We are excited to have an even closer working relationship with our friends and partners at KMS,” adds Holger Schade, CEO of VertiGIS EMEA. “This transaction will drive additional innovation as we extend our technological capabilities to a broader group around the globe.”
“Facility management solutions are a key strength of VertiGIS’, and the shared development plans for ProOffice and GEBman fit perfectly into our product strategy moving forward.”
About VertiGIS:
VertiGIS is a leading geographic information systems (GIS) solution provider and software developer. Its focus is the development of software solutions and services that help utilities, land management, public sector, energy, telecommunications, and industry customers connect their business processes and location technology. The VertiGIS product portfolio is used by thousands of customers and millions of end-users around the world and is designed to enhance the capabilities of leading mapping software, most notably Esri’s ArcGIS®. Major product brands include UT for ArcGIS®, the 3A product line, Geocortex®, GEONIS, ConnectMaster™, M4® Solutions, GeoOffice, WebOffice and ProOffice. Further information can be found at www.vertigis.com
About Battery Ventures:
Battery strives to invest in cutting-edge, category-defining businesses in markets including software and services, Web infrastructure, consumer Internet, mobile and industrial technologies. Founded in 1983, the firm backs companies at stages ranging from seed to private equity and invests globally from offices in Boston, the San Francisco Bay Area, London, Israel and New York. Follow the firm on Twitter @BatteryVentures, visit our website at www.battery.com and find a full list of Battery's portfolio companies here.
About KMS:
KMS is an established and proven provider of computer-aided facility management (CAFM) software based in Dresden, Germany. KMS is known for its GEBman software and has been supporting municipalities, industrial, service and utility companies, among others, with their facility and document management requirements since 1990. The flexible, end-to-end solutions are based on the latest web technologies and are suitable for internal or mobile use. Learn more at www.gebman.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210414005039/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom